Successful treatment of mast cell sarcoma of the uterus with imatinib.
Mast cell sarcoma is a rare disease characterized by localized, but destructive and rapid, growth of the tumor, high risk of distant metastasis, possibility of a leukemic phase, and poor prognosis. We report successful treatment of uterine mast cell sarcoma with imatinib in a 39-year-old woman who presented with abdominal distention and massive ascites. Routine treatment, such as combined chemotherapy, had little effect. We administered imatinib to the patient and achieved a good response in the absence of c-kit mutation, BCR/ABL, and FIP1L1-PDGFRα. Our results indicate that imatinib is of potential use in the treatment of mast cell sarcoma.
Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
Hong Bing
HB
Ma
Xia
X
Xu
Wei Ping
WP
Liu
Hong
H
Chang
Fan
F
Zeng
Yu Chun
YC
Wang
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D005260:Female; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D012515:Mast-Cell Sarcoma / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000008:administration & dosage*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage*; D020796:Receptor, Platelet-Derived Growth Factor alpha; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D039221:mRNA Cleavage and Polyadenylation Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha